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+Roman L .  Hruska U.S. Meat Animal Research Center, ARS, USDA, Clay Center, NE 68933 
ABSTRACT: Forty wether lambs were used in a 2 
x 4 factorial arrangement to determine the response of 
animal performance, muscle growth, proteinase ac- 
tivity, and meat tenderness to 0-adrenergic agonist 
(BAA) supplementation. Lambs were fed a finishing 
diet with or without 4 ppm of L644,969 and slaughtered 
after 0, 2, 4, and 6 wk of treatment. The ADG was 
higher (P < .05) in the treated than in the control 
lambs after 2 wk and returned to control levels 
thereafter. Semitendinosus weight and calpastatin 
activity were higher and p-calpain activity was lower 
in the treated than in the control lambs after 2, 4, and 
6 wk. Cathepsin B activity was higher ( P < .0 1) and 
cystatin-like activity was lower ( P  c .05) after 2 wk in 
treated than in control lambs but returned to control 
levels thereafter. Longissimus protein:DNA was 
higher after 4 ( P  < .05) and 6 ( P  < .01) wk in the 
treated lambs than in the controls. The concentration 
of RNA and RNA:DNA ratio were higher ( P < .0 1) in 
the longissimus and semitendinosus muscles in the 
treated lambs after 2 wk and remained higher 
throughout the study. Semitendinosus protein and 
RNA content were higher after 2, 4, and 6 wk and 
DNA content was higher after 2 and 6 wk in the 
treated than in the control lambs. Longissimus shear- 
force values were higher ( P  < .001) in the treated 
than in the control lambs at all slaughter end points. 
These data indicate a rapid alteration of muscle 
growth, activity of the calpain-calpastatin system, and 
meat tenderness during BAA treatment. It also seems 
that the BAA-stimulated muscle growth is closely 
related to the activity of the calpain-calpastatin 
system. 
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Introduction 
Protein turnover involves two cellular processes, 
protein synthesis and degradation. Protein turnover 
decreases an animal's growth efficiency, because of 
energy lost during the breakdown and resynthesis of 
proteins. These processes are inefficient but necessary 
for maintaining available pools of amino acids, repair- 
ing erroneous proteins, and removing proteins not 
properly incorporated into their subcellular locations 
(Reeds, 1989). Young et al. (1975) suggested that 15 
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to 25% of the energy consumption of growing animals 
was used for protein turnover. Thus, a better under- 
standing of the regulation of in vivo protein degrada- 
tion could allow large alteration of animal growth 
efficiency and consequently reduce the cost of produc- 
tion. 
The 6-adrenergic agonists have been shown to 
increase muscle accretion and decrease fat accretion 
(Yang and McElligott, 1989). These compounds have 
been reported to regulate both protein synthesis 
(Maltin et al., 1987; Helferich et al., 1990) and 
protein degradation (Reeds et al., 1986; Bohorov et 
al., 1987). In most cases, the greatest effect is on 
protein degradation. Recently, the endogenous pro- 
teinases ( the calpain system and the cathepsins) have 
been studied during P-adrenergic-agonist supplemen- 
tation (Forsberg et al., 1989; Kretchmar et al., 1990; 
Koohmaraie et al., 1991). Most of the data indicate 
that activity of calpastatin, the endogenous inhibitor 
of p- and m-calpain, increases substantially during the 
treatment period. Although data from laboratory 
animals have shown short-term responses to 
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Table 1. Dry matter composition of the diet 
Ingredient % DM 
Corn 64.83 
Alfalfa hay 20.00 
Molasses 6.00 
Soybean meal (60% CP) 7.94 
Limestone .82 
Dicalcium phosphate .06 
Salt .30 
Vitamin premixa .02 
S h e e ~  trace mineral memixb .03 
'Vitamin A, 15,000 IUig, vitamin D, 3,000 IUig; vitamin E, 3.75 
IU/ 
f77.7% soyhulls; 12.3% MnS04; 7.0% ZnC03; 3.0% oil or fat. 
P-adrenergic agonists (Reeds et al., 1986; Maltin et 
al., 1987), most of the data collected in livestock have 
been over long time periods. Therefore, this study was 
designed to investigate the response time of muscle 
growth, endogenous proteinase activity, and meat 
tenderness to P-adrenergic-agonist treatment in 
wether lambs. 
Exper imenta l  Procedures  
Experimental Design. Forty wether lambs (112 
Finnsheep, 114 Dorset, 114 Ramboillet) with an 
average weight of 35.2 + .6 kg were assigned to a 
factorial arrangement with two dietary treatments 
(control and treated) and four treatment periods (0, 
2, 4, and 6 wk). The lambs were ranked by weight, 
divided into five groups of eight, and randomly 
assigned to the eight treatments. The control diet was 
a corn, alfalfa hay diet containing 14% CP (Table 1). 
The treated diet consisted of 4 ppm of the 6-adrenergic 
agonist L644,969 (Merck, Sharp and Dohme Research 
Laboratories, Rahway, NJ)  added to the control diet. 
Daily feed consumption and biweekly live weights 
were recorded. The lambs were weighed on three 
consecutive days to start the test. After the assigned 
treatment period, the lambs were weighed, trans- 
ported to the University of Nebraska Meat Labora- 
tory, and slaughtered. Within 45 min postmortem, the 
longissimus muscle was removed from one randomly 
chosen side and sampled for determination of activity 
of the calpain system and cathepsins B and L as well 
as concentrations of DNA, RNA, and protein. Within 1 
to 2 h postmortem, the semitendinosus muscle from 
the same side was removed intact, weighed, and 
sampled for determination of DNA, RNA, and protein 
concentration. 
The longissimus muscle from the other side of the 
carcass was removed after it had been stored for 48 h 
at 4°C and divided in half, and the halves were 
randomly assigned to either 2 or 7 d of aging. A 
5-g slice of the loin was removed for sarcomere length 
determination and stored at -20°C. The loin halves 
were vacuum-packaged and stored at 4°C until 
completion of the assigned aging time. The loin halves 
were then frozen at -35°C and stored at -20°C until 
shear force was measured. 
Determination o f  Calpain Activity. Activity of p- 
calpain, m-calpain, and calpastatin were determined 
on unfrozen, prerigor muscle according to the proce- 
dures of Koohmaraie ( 1990), with some slight modifi- 
cations. Longissimus muscle samples (50 g)  were 
homogenized in 2.5 volumes of extraction buffer (100 
mM Tris, 5 mM EDTA, and 10 mM 0-mercaptoethanol 
[MCEI, pH 8.3). The samples were then centrifuged, 
filtered, and dialyzed overnight in dialysis buffer (20 
mM Tris, 5 rnM EDTA, 10 mM P-MCE, pH 7.5). After 
dialysis, the samples were loaded onto anion exchange 
(2-[diethylamino] ethyl ether [DEAEI-Sephacel; 
Sigma Chemical, St. Louis, MO) columns and washed 
with three volumes of elution buffer (20 mM Tris, . l  
mM EDTA, and 10 mM P-MCE, pH 7.35). The 
samples were then eluted using a linear NaCl 
gradient (0 to 400 mM), and 130 fractions (6  mL) 
were collected. Activity of the proteinases and the 
inhibitor were determined using a casein solution 
(100 mM Tris, 1 mM NaN3, 5 mM CaC12, 1 pLlmL of 
0-MCE, and 5 mg1mL of casein, pH 7.5). One unit of 
proteinase activity was defined as the amount of 
enzyme necessary to cause an increase of 1.0 optical 
density unit at 278 nm. One unit of inhibitor activity 
was defined as the amount of calpastatin necessary to 
inhibit one unit of DEAE-purified m-calpain activity. 
Cathepsin B and L and Cystatin-like Activity. 
Activity of the cathepsins and their inhibitor were 
determined on frozen muscle samples according to 
method D of Koohmaraie and Kretchmar (1990). 
Longissimus samples ( 5 g)  were homogenized in 
seven volumes of extraction buffer (50 mM sodium 
acetate, 1 mM EDTA, 100 mM NaC1, and .2% Triton 
X-100, pH 5.0). After homogenization, the samples 
were centrifuged and filtered and 2 mL of the extracts 
was passed through a papain-Sepharose affinity 
column to remove the cystatins, endogenous inhibitors 
of the cathepsins. The samples, pre- and postcolumn, 
were assayed using synthetic substrates (cathepsin B, 
Z-Arg-Arg-NMec; cathepsin B + L, Z-Phe-Arg-NMec; 
Bachem Fine Chemicals, Torrence, CA). The sub- 
strate used for cathepsin L is also a substrate for 
cathepsin B; therefore, the specific activity is reported 
as B + L. Specific activity of the cathepsins was 
reported as the nanomoles of NMec 
released.minute-l.gram of tissue. Cystatin-like ac- 
tivity was reported as the ratio of post-:precolumn 
cathepsin B + L activity. 
Nucleic Acid and Protein Concentrations. Concen- 
trations of DNA were determined fluorometrically 
using Hoechst 33258 (Sigma Chemical; Labarca and 
Paigen, 1980). Concentrations of RNA were measured 
spectrophotometrically using the procedures of Munro 
and Fleck ( 19691, and protein concentrations were 
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Table 2. Changes in average daily gain, hot carcass weight, dressing percentage, 
and longissimus cathepsin B, B + L, and cystatin-like activity of lambs 
after P-adrenergic agonist (BAA) treatment 
Time on feed, wk 
Trait 0 2 4 6 
Average daily gain, kg 
Control 
BAAa 
Hot carcass wt, kg 
Controla 
BAAa 
Dressing percentage, % 
Control 
BAAa 
Cathepsin B, nmol ~ ~ e c . r n i n - l . ~ - '  
Control 
sAAb 
Cathepsin B + L, 
nmol ~ ~ e c . m i n - l , ~ - l  
Control 
BAA 
Cystatin-like activityC 
Control 
BAA 
aLinear effect, P < .01. 
b ~ u a d r a t i c  effect, P < .05. 
'See text for description. 
*, **Means within a trait, a t  a specific time on feed, differ, P < .05 and .01, respectively. 
determined using the biuret procedure of Gornall et al. 
(1949). 
Determination o f  Sarcomere Length. Sarcomere 
lengths were measured according to the procedure of 
Cross et al. (1981), modified for use with a Zeiss 
microscope (LEP, Scarsdale, NY) attached to a 
BioQuant System VI digitizer (Houston Instrument, 
Austin, TX). Longissimus samples (5  g )  were 
homogenized in eight volumes of 250 mM sucrose and 
measurements recorded for 10 adjacent sarcomeres on 
each of 10 different myofibrils. 
Determination o f  Warner-Bratzler Shear Force. 
Loin roasts used for Warner-Bratzler shear (WBS) 
force determination were thawed at 4°C for 24 h and 
oven-roasted to an internal temperature of 70°C. 
Internal temperatures were monitored using copper- 
constantan thermocouples. Six to eight cores (1.3 cm) 
were removed randomly from each sample, parallel to 
the longitudinal orientation of the fiber. Cores were 
sheared once using the WBS blade attached to an 
Instron Universal Testing Machine (Model 1123, 
Instron, Canton, MA). 
Statistical Analyses. The data were analyzed using 
ANOVA for a completely randomized design (Steel 
and Torrie, 1980). The treatment means for animal 
performance, muscle weight, proteinase activity, nu- 
cleic acid and protein concentration, and sarcomere 
length of treated and control lambs at specific 
slaughter end points were separated using single df 
contrasts. The WBS means for treated and control loin 
portions at  specific slaughter end points and at specific 
aging times were separated using single df contrasts. 
The means for 2 and 7 d of aging at specific slaughter 
end points in treated and control loin portions were 
also separated using single df contrasts. The data are 
presented as means + SEM. Different values for SE 
within a trait are due to differences in the number of 
observations for means. 
Results 
Animal Performance and Muscle Growth. Average 
daily gain was higher ( P  < .05) after 2 wk of 
treatment and returned to control levels thereafter 
(Table 2). Daily feed intake and feed efficiency were 
not affected ( P  > .30 and > .45, respectively) by BAA 
treatment (data not shown). Hot carcass weight was 
numerically higher (P  > .lo; Table 2 ) and backfat was 
numerically lower ( P  > . lo;  data not shown) in the 
BAA lambs than in control lambs. In accordance with 
most BAA studies, dressing percentage was increased 
by 6% after 2 wk ( P  < .05) and by 8% after 4 and 6 wk 
( P  c .05) of BAA treatment. Muscle accretion, 
indicated by semitendinosus weight (Figure I ) ,  was 
higher in BAA-treated lambs than in control lambs 
after 2 wk ( P  < .05) and remained higher after 4 and 
6 wk ( P  c .01) of BAA supplementation. This 
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SEMITENDINOSUS WEIGHT 
-..- - 
(Treatment menna differ, P < .05) 
20.0 ** (Treatment means dWw, P < .01) 
140.0 
120.0 
'o0.0 
0 
% 
.- g 
Time on feed (wk) 
** 
** 
,_._.._ ..-. -..-.' 
_,,__.__ -.. -...
- 
- *,.. 
..I" 
,-+ 
- Le4,Bee control 
Figure 1. The response of semitendinosus weight to 
0-adrenergic agonist feeding in lambs. 
indicates that the increased growth rate of the BAA- 
treated lambs is primarily due to increased muscling. 
Calpains and Calpastatin Activities. Activity of m- 
calpain was not significantly affected ( P  > .60) by 
BAA treatment (data not shown). Activity of p- 
calpain was significantly lower after 2 and 6 wk of 
BAA treatment and tended to be lower ( P  < .20) after 
4 wk of treatment (Figure 2).  Conversely, calpastatin 
activity was 73% higher in BAA-treated lambs than in 
control lambs after 2 wk ( P < .0 1) and remained 
significantly higher throughout the study (Figure 3). 
Collectively, these data indicate a decrease in the 
proteolytic capacity of BAA-treated muscle; the 
greatest response occurred within 2 wk. 
Cathepsins B and B + L and Cystatin-like Activi- 
ties. Cathepsin B activity was higher ( P < .0 1) and 
cystatin-like activity was lower (P  < .05) in BAA- 
treated lambs than in control lambs after 2 wk and 
p-CALPAIN ACTIVITY 
I (Treatment meana differ, P < .05) I I I I I 
0 2 4 6 
Time on feed (wk) 
returned to control levels after 4 wk (Table 2). 
Cathepsin B + L activities did not differ ( P  > .25) 
between treated and control lambs (Table 2 j. Thus, it 
seems unlikely that the increased muscle accretion 
(Figure 1) of the treated lambs was due to altered 
activity of lysosomal proteinases. 
Longissirnus Nucleic Acids and Protein Concentra- 
tions. The protein:DNA ratio (Table 31, an indicator 
of cell mass or size, was greater in the BAA-treated 
than in the control lambs after 2, 4 ( P  < .05), and 6 
wk ( P  < .01). Longissimus protein concentration 
increased linearly in both the treated ( P  < .05) and 
control ( P  < . l o )  lambs but did not differ significantly 
at  any slaughter end point. The increased protein: 
DNA ratio in the treated lambs is consistent with 
previous data on BAA treatment (Kim et al., 1987; 
Koohmaraie et al., 1991) and agrees with the theory 
that BAA-stimulated muscle growth is hypertrophic. 
Longissimus RNA concentrations in the control 
lambs decreased progressively during the 6-wk feeding 
trial (Table 3) .  The RNA concentrations in the BAA- 
treated lambs were 21% higher than in the control 
lambs after 2 wk ( P < .0 1) and remained higher 
throughout the study. Longissimus RNA:DNA ratio, 
an indicator of transcriptional activity, exhibited the 
same pattern of changes as RNA concentration during 
the study. Conversely, the protein:RNA ratio, an 
indicator of translational activity, decreased to a value 
less than that in control lambs after 2 wk ( P  < .05j of 
BAA treatment and remained lower through 4 and 6 
wk (Table 3) .  
Sernitendinosus Nucleic Acid and Protein Concen- 
trations and Contents. Unlike the longissimus muscle, 
the semitendinosus protein:DNA ratio was not signifi- 
cantly affected ( P  > .5) by BAA treatment (Table 4). 
Likewise, BAA treatment did not affect ( P  > .5) the 
protein concentration (Table 4).  Changes in the RNA 
concentration of the semitendinosus muscle were 
similar to those in the longissimus (Table 4) ;  RNA 
CALPASTATIN ACTIVITY 
** 
2 4 
Time on feed (wk) 
Figure 2. The response of longissimus muscle p-  Figure 3. The response of longissimus muscle 
calpain activity to P-adrenergic agonist feeding in calpastatin activity to P-adrenergic agonist feeding in 
lambs. lambs. 
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Table 3. Changes in longissimus protein:DNA ratio, protein and RNA 
concentration, and RNA:DNA and protein:RNA ratios of lambs 
after P-adrenergic agonist [BAA) treatment 
Time on feed, wk 
Trait 
Protein:DNA, mg/mg 
Control 
BAAa 
Protein, mglg of tissue 
Control 
 BAA^ 
RNA, mgig of tissue 
Controla 
BAAC 
RNA:DNA, mgimg 
Controla 
 BAA^ 
Protein:RNA, mgimg 
Controla 
 BAA^ 
aLinear effect, P i .01. 
b ~ i n e a r  effect, P i .05. 
cQuadratic effect, P < . lo .  
d ~ u a d r a t i c  effect, P < .05. 
*, **Means within a trait, a t  a specific time on feed, differ a t  P < .05 and .01, respectively. 
concentration in the control lambs decreased progres- < .05) and 4 ( P  < .01) wk. However, in contrast to the 
sively during the feeding period, whereas RNA concen- longissimus data, semitendinosus RNA:DNA ratio in 
tration in the BAA-fed lambs increased after 2 wk and BAA-fed lambs was similar to controls after 6 wk of 
then decreased to levels found in the 0-wk treated treatment (Table 3 and 4) .  Although lower a t  all end 
lambs. As previously noted in the longissimus muscle, points, the protein:RNA ratio of the semitendinosus 
the semitendinosus RNA:DNA ratio was higher in the muscle was only significantly lower ( P  < . l o )  after 4 
treated animals than in the control animals after 2 (P  wk of BAA treatment (Table 4). 
Table 4. Changes in semitendinosus protein:DNA ratio, protein and RNA 
concentration, and RNA:DNA and protein:RNA ratios of lambs 
after /3-adrenergic agonist (BAA) treatment 
Time on feed, wk 
Trait 0 2 4 6 
Protein:DNA, mgimg 
Control 290.2 + 15.6 
BAA 279.8 + 15.6 
Protein, mg/g of tissue 
Control 251.2 + 8.4 
BAAa 246.3 f 8.4 
RNA, m g of tissue %' Control 563.9 f 20.0 
BAAC 537.5 f 17.9 
RNA:DNA, mdmg 
Control .66 f .04 
 BAA^ .61 -f- .03 
Protein:RNA, mg/mg 
controlb 445.7 f 21.9 
BAAa 459.1 f 19.6 
aLinear effect, P c .05. 
b ~ i n e a r  effect, P < .01. 
CQuadratic effect, P < .lo. 
d ~ u a d r a t i c  effect, P c .01. 
+, *, **Means within a trait, a t  a specific time on feed, differ a t  P < .lo, .05, and .01, respectively. 
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WARNER-BRATZLER SHEAR FORCE 
** 
0 1 1  I I I 
0 2 4 6 
Time on feed (wk) 
Figure 4. The response of Warner-Bratzler shear 
force to 0-adrenergic agonist feeding and subsequent 
aging in lamb longissimus muscle. Within a time 
period, L644,969 means were higher (P < .001) than 
controls. 
Nucleic acid and protein contents were calculated 
by multiplying the concentrations of each by the 
weight of the semitendinosus muscle. Although the 
concentrations of DNA were lower in the BAA-treated 
animals than in the controls (data not shown), the 
total amount of DNA (Table 5 )  was higher in the 
treated lambs after 2 wk ( P  < . l o )  and 6 wk (P  < .01). 
Similar data have been reported in lambs (Beermann 
et al., 1987) and rabbits (Forsberg et al., 1989); 
however, Koohmaraie et al. (1991) and Kim et al. 
(1987) reported a decrease in the concentrations of 
DNA in treated animals without a change in the total 
amount of DNA. Because of the combined responses in 
muscle weight and RNA and protein concentrations, 
the RNA and protein content of the semitendinosus 
muscle in BAA-treated lambs was higher (P  < .05) 
than in control lambs at all end points. 
Longissirnus Tenderness and Aging. The Warner- 
Bratzler shear force values for longissimus muscle 
aged 2 d (WBS2) and 7 d (WBS7) are presented in 
Figure 4. Both the WBS2 and WBS7 values were 
higher ( P  < .001) in the treated lambs than in the 
control lambs after 2, 4, and 6 wk. Sarcomere length 
was not affected (P  > .25) by BAA treatment (data 
not shown). The tenderness data agree with the 
findings of Hamby et al. (1986), Miller et al. (1988), 
Morgan et al. (1989), and Koohmaraie and Shackel- 
ford (1991), who also found that BAA treatment 
decreased muscle tenderness. Our data also concur 
with the observation of Merkel (1988) that the 
decreased tenderness in BAA-treated animals could 
not be explained by muscle shortening. 
The response to aging, indicated by the difference 
between WBS2 and WBS7, varied with treatment 
(Figure 4). There were no significant differences 
between WBS2 and WBS7 in the BAA-treated lambs 
after 2 and 6 wk of treatment; however, after 4 wk of 
BAA treatment WBS7 was 21% lower ( P < .05) than 
WBS2. This was due mainly to an increase in the 
WBS2 value at that end point and not to a reduction 
in WBS7. In the control lambs, WBS7 was 35 and 32% 
lowerthanWBS2after4(P<.05)  a n d 6 ( P < . l 0 )  wk 
of the study, respectively. The decreased response to 
aging in BAA-treated lambs has also been reported by 
Kretchmar et al. (1990), Koohmaraie and Shackelford 
(1991), and Koohmaraie et al. (1991). 
Discussion 
The effects of BAA on animal performance vary. In 
our study, L644,969 supplementation increased ADG 
during the first 2 wk of treatment and had no effect 
thereafter. Other studies have shown early increases 
in ADG (Beermann et al., 1986; Moloney et al., 1990), 
longer-term effects on ADG (Kim et al., 1987; 
Table 5. Changes in DNA, RNA, and protein content of lamb 
semitendinosus muscle after 0-adrenergic agonist (BAA] treatment 
Time on feed, wk 
Trait 0 2 4 6 
DNA, mg 
Control 78.3 f 6.1 82.7 f 6.1t 89.3 i 6.1 82.8 f 6.1** 
BAAa 78.9 k 6.1 98.5 f 6.1 98.6 k 6.1 113.7 f 6.8 
RNA, mg 
Control 50.7 k 4.2 49.7 f 3.7** 50.2 i 3.7** 48.9 + 3.7** 
 BAA^^ 48.7 i 3.7 68.3 f 3.7 68.3 i 3.7 70.3 f 3.7 
Protein, g 
Control 22.9 i 1.8 24.8 f 1.8* 26.0 i 1.8* 27.3 f 1.8** 
BAAa 22.0 i 1.8 31.0 f 2.1 31.9 i 1.8 36.7 f 1.8 
aLinear effect, P < .01. 
b ~ u a d r a t i c  effect, P < .05. 
+, *, **Means within a trait, a t  a specific time on feed, differ a t  P < .lo, .O5, and .01, respectively. 
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Anderson et a]., 1989; Koohmaraie et al., 19911, and 
no BAA effect on ADG (Bohorov et al., 1987; Claeys et 
al., 1989). The varied response in ADG may be due to 
the type and dose of BAA, animal age, or the length of 
treatment. Beermann et al. (1986), Claeys et al. 
(1989), and Williams et al. (1989) have all reported 
that young lambs (<  20 kg) do not show a response in 
ADG or feedlgain during BAA treatment. This may be 
caused by a lower number of P-adrenergic receptors 
(BAR) or by a reduction in the ability to stimulate 
postreceptor events upon binding of the BAA to the 
BAR (for review see Stiles et al., 1984). 
The most consistent response noted in BAA-treated 
animals is an increase in the weight of various 
muscles (Yang and McElligott, 19891, with the most 
prominent increase in muscles dominated by Type I1 
fibers (Beermann et al., 1987). Based on the results of 
this study and other studies using lambs (Wang and 
Beermann, 1988) and rats (Reeds et al., 19861, it 
seems that BAA administration has its greatest effect 
on muscle growth during the first 2 to 3 wk of 
treatment. This muscle accretion could occur from 
increased protein synthesis, as reported for pigs fed 
ractopamine (Helferich et al., 1990) and rats fed 
clenbuterol and fenoterol (Emery et al., 1984) or from 
decreased protein degradation, as reported for lambs 
(Bohorov et al., 1987) and rats (Reeds et al., 1986) 
fed clenbuterol. Alternatively, Anderson et al. (1991) 
suggested a biphasic response of muscle to BAA 
treatment, whereby protein degradation was initially 
reduced followed by increased protein synthesis with 
chronic treatment. 
Administration of BAA has been reported to de- 
crease the proteolytic capability of the muscle through 
alteration of the calpain-calpastatin complex (Higgins 
et al., 1988; Wang and Beermann, 1988; Forsberg et 
al., 1989; Kretchmar et al., 1989; Koohmaraie et al., 
1991). We found that the greatest changes in activity 
of this system occurred during the first 2 wk of 
treatment and involved a decrease in p-calpain 
activity, an increase in calpastatin activity, and no 
change in m-calpain activity. The similarity between 
the response of calpastatin activity (Figure 3 )  and 
muscle weight (Figure 1 ) suggests that an increase in 
calpastatin activity may be related to BAA-induced 
muscle growth. 
The results from BAA treatment on the cathepsins 
vary, with reports of increased activity (McElligott et 
al., 1987; Koohmaraie et al., 1991), decreased activity 
(Kretchmar et al., 1989; Morgan et al., 1989; B6chet 
et al., 1990), or no change in activity (Forsberg et al., 
1989). In our study, activity of the catheptic system 
increased, suggesting an increase in the proteolytic 
capability of the longissimus muscle (Table 2) .  
Although the role of the catheptic proteinases in 
skeletal muscle turnover is unknown, the increased 
cathepsin activity in BAA-treated animals in the 
present study did not prevent an increased rate of net 
muscle protein accumulation. Go11 et al. (1989) 
suggested a role for this system in the control of 
sarcoplasmic protein turnover. 
Most researchers have proposed a hypertrophic 
model for BAA-induced muscle growth (Beermann et 
al., 1987; Kim et al., 1987; Koohmaraie et a]., 1991), 
as  opposed to models for compensatory muscle growth 
(Beermann, 1983) or somatotropin-induced muscle 
growth (for review see Boyd and Bauman, 1989). Our 
longissimus data are consistent with these findings. 
The semitendinosus data (Table 4 )  also agree with 
the hypertrophic model of growth up to 4 wk of 
treatment. However, after 6 wk of treatment, the 
semitendinosus muscle seemed to grow through some 
mechanism other than strict hypertrophy. Although 
the incorporation of satellite cells or hyperplastic 
muscle growth is not consistent with most of the BAA 
data, it has been suggested as a possibility in rabbits 
fed cimaterol (Forsberg et al., 1989) and may 
partially explain the long-term differences noted in 
semitendinosus weight. 
In agreement with previous studies (Beermann et 
al., 1987; Williams et al., 1989; Koohmaraie et al., 
1991), the present study finds that transcriptional 
activity (RNA:DNA ratio) is higher in muscle from 
BAA-fed animals than in muscle from control animals. 
There was attenuation in the transcriptional activity 
of muscle from BAA-treated lambs after 4 and 6 wk. 
Attenuation to BAA treatment has been reported 
previously (Eisemann et al., 1988; Yang and McE1- 
ligott, 1989) and may be due to down-regulation of the 
BAR. Kim et al. (1 992) reported this phenomenon in 
rat skeletal muscle, noting a 26.8% decrease in the 
number of 0-adrenergic binding sites with 3 d of BAA 
treatment. Our data are consistent with the fact that 
translational activity, protein:RNA ratio, of muscle is 
generally not altered by BAA treatment. Collectively, 
the nucleic acid and protein data in our study and 
previous studies suggest that BAA treatment in- 
creases the protein synthetic capacity of muscle. As 
suggested by Anderson et al. (19911, our data imply 
that the decreased muscle protein degradation, due to 
changes in the calpain/calpastatin complex, coupled 
with the increased muscle protein synthetic capacity 
may account for the lean growth of BAA-treated 
animals. 
Our tenderness data agree with previous findings 
(Morgan et al., 1989; Koohmaraie and Shackelford, 
1991; Koohmaraie et al., 1991) that the meat from 
BAA-treated animals is consistently tougher than 
untreated meat and responds less favorably to aging. 
Responses of shear force (Figure 4) and calpastatin 
activity (Figure 3)  were similar, and elevated cal- 
pastatin activity has been implicated in BAA-induced 
toughening of meat (Koohmaraie et al., 1991). These 
data imply that the increase in calpastatin activity 
may be related to both the decreased tenderness and 
decreased response to aging in meat from BAA-treated 
animals. 
Because this study monitored the effects of BAA 
administration over a 6-wk period, it was possible to 
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show the rapid response and subsequent attenuation 
elicited by these compounds. Measurable changes 
occur in muscle weight and metabolism within 2 wk of 
treatment. Also, there seems to be a differential 
response of the longissimus and semitendinosus mus- 
cles to BAA treatment. Kim et al. (1987) and 
Beermann et al. (1987) reported that muscle fiber 
type influenced the response of muscle to BAA 
treatment. They noted a larger growth in the Type I1 
(glycolytic) fibers than in the Type I (oxidative) 
fibers, which may explain some of the differential 
responses in the two muscles measured in this study. 
Implications 
This study shows that the /3-adrenergic agonists 
may act on the calpain-calpastatin system to stimu- 
late muscle growth through a decrease in protein 
degradation. Decreased protein degradation has been 
suggested as the most efficient means of increasing 
muscle protein accretion. Therefore, a better under- 
standing of the mechanisms that control these pro- 
teinases and protein degradation may allow improve- 
ment of animal growth efficiency. 
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